Biotech entity

Independent Data Monitoring Committee

organization

All 1 tracked stories fall under one category: pharma. Independent Data Monitoring Committee is most often covered alongside ACTION3, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Independent Data Monitoring Committee, all published on July 12, 2026.

Last mentioned: Jul 12, 2026

RSS updates
Share

Entity pulse

Recent coverage · Independent Data Monitoring Committee

1 story
6 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Independent Data Monitoring Committee

All 1 tracked stories fall under one category: pharma. Independent Data Monitoring Committee is most often covered alongside ACTION3, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Independent Data Monitoring Committee, all published on July 12, 2026. Each carries 4 original sources on average.

Stories tracked
1
Sources per story
4

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Independent Data Monitoring Committee. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Exclusive License Agreement

    Dimerix announces licensing deal with Everest Medicines for Asian commercialization.

  2. Eighth DSMB Safety Review

    Independent committee finds no safety concerns in ongoing trial.

  3. Statistical Power Confirmation

    External blinded review confirms the trial retains over 90% statistical power for the primary endpoint.

  4. Positive Interim Results

    Dimerix reports DMX-200 performing better than placebo in reducing proteinuria in the ACTION3 adult cohort.

Stories mentioning Independent Data Monitoring Committee 1

Independent Data Monitoring Committee is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.